Table 3.
Vaccines recommendations in chronic kidney disease (CKD) patients and kidney transplant (KT) recipients.
| Pre-Transplant | Post-Transplant | |||
|---|---|---|---|---|
| Timing | Schedule | Timing | Schedule | |
| Influenza | Each winter, at least 2 weeks prior KT | Single dose | 3–6 months after KT (as early as 1 month after KT in case of outbreak but avoiding LAV) | Single dose |
| Streptococcus pneumoniae | At least 2 weeks prior KT | PCV13 followed by PPSV23 8 weeks later | 3–6 months after KT | PCV13 followed by PPSV23 8 weeks later |
| HBV | At least 2 weeks prior KT | 0, 1 and 2 and/or 6 months depending on type of vaccine | 3–6 months after KT | 0, 1 and 6 months |
| HAV | At least 2 weeks prior KT | As general population | 3–6 months after KT | As general population |
| SARS-CoV-2 | At least 2 weeks prior KT | As general population | 3–6 months after KT | As general population |
| HZV | 2 weeks for RZV | As general population | HZV not recommended, RZV, 3–6 months after KT | 2 doses at least 8 weeks apart |
| Meningococcal | At least 2 weeks prior KT | As general population | 3–6 months after KT | As general population |
| HPV | At least 2 weeks prior KT | As general population | 3–6 months after KT | 0, 2, 6 months, monovalent vaccine up to 45 years |
| MMR | At least 4 weeks pre-KT | As general population | Not recommended | - |
| Tetanus, Tdap/Td, Haemophilus influenza type B | At least 2 weeks prior KT | As general population | 3–6 months after KT | As general population |
| Yellow fever | At least 4 weeks pre-KT | As general population, in case of travel to at-risk areas | Not recommended | - |
| Polio | At least 4 weeks pre-KT | As general population | Inactivated, 3–6 months after KT | As general population |
| Rabies | At least 2 weeks prior KT | As general population | 3–6 months after KT | 0, 7, 21 days |
| Rotavirus, BCG, Smallpox, Cholera | At least 4 weeks pre-KT | As general population | Not recommended | - |
KT, kidney transplant; CKD, chronic kidney disease; LAVs, live attenuated vaccines; LZV, live attenuated zoster vaccine; PCV13, 13-valent pneumococcal conjugate vaccine; PPSV23, 23-valent pneumococcal polysaccharide vaccine; RZV, recombinant zoster vaccine; HAV, hepatitis A virus; HBV, hepatitis B; HPV, human papilloma virus; HZV, herpes zoster virus; MMR, measles, mumps and rubella; Tdap, tetanus toxoid, reduced diphtheria toxoid, acellular pertussis; Td, tetanus diphtheria; BCG, bacille Calmette–Guerin.